Gain of function mutations in CAPS patients leads to hyperactive cryopyrin inflammasome, increased myeloid cell-derived proinflammatory cytokine release, and systemic and tissue inflammation leading to disease symptoms. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.